Last reviewed · How we verify
Other Statin
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events.
At a glance
| Generic name | Other Statin |
|---|---|
| Sponsor | Organon and Co |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking HMG-CoA reductase, statins decrease hepatic cholesterol production and upregulate LDL receptor expression on liver cells, leading to increased clearance of LDL cholesterol from the bloodstream. This mechanism reduces cardiovascular risk by lowering atherogenic lipid levels and may provide additional pleiotropic anti-inflammatory benefits.
Approved indications
- Hypercholesterolemia
- Primary prevention of cardiovascular disease
- Secondary prevention of cardiovascular events
Common side effects
- Myalgia (muscle pain)
- Elevated liver transaminases
- Rhabdomyolysis
- Headache
Key clinical trials
- Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- NOTIFY (New Observations Taking Information From Yesterday) (NA)
- ISCHEMIA-EXTEND (Extended Follow-up)
- A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
- Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques (PHASE4)
- COAST Study - Cholesterol Optimization After Stroke
- The Precision CAD Trial (NA)
- Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other Statin CI brief — competitive landscape report
- Other Statin updates RSS · CI watch RSS
- Organon and Co portfolio CI